Ralph Zinner

Professor

University of Kentucky
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Purpose: In locally advanced resectable squamous cell carcinoma of the head and neck (SCCHN), patients treated with neoadjuvant chemotherapy with major pathologic response (MPR) or pathologic complete response (pCR) have overall survival (OS) rates superior to those of patients with poorer pathologic responses. To improve efficacy, we added the PD-1 inhibitor nivolumab to neoadjuvant chemotherapy and evaluated the combination. Patients and Methods: In this single-arm, open-label phase II trial, patients with newly diagnosed stage III to IV human papillomavirus (HPV)–negative SCCHN in the oral cavity, oropharynx, hypopharynx, and larynx or stage II to III HPV-positive oropharyngeal SCCHN received neoadjuvant carboplatin and paclitaxel (6 weeks) plus nivolumab (every other week), followed by surgery and adjuvant radiotherapy ± chemotherapy. The primary endpoint was pCR at the primary site. Results: Thirty-four patients were enrolled and received neoadjuvant therapy. Thirty-three patients received surgery (R0 resection = 100%). Disease sites included the oral cavity (79%), oropharynx (12%), hypopharynx (6%), and larynx (3%). Twenty-eight (85%) patients had stage IVA disease. The median postsurgical follow-up was 35.3 months. Fourteen (41%) patients had grade 3/4 treatment-related adverse events. Twenty-seven (82%) patients completed all cycles of neoadjuvant therapy. Twenty-four (73%) patients had at least an MPR at the primary site, and 15 (45%) had a pCR. In an unplanned analysis at 3 years, recurrence-free survival and OS were 74% and 83%, respectively. Conclusions: This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN.

Year:

2026

Year:

2025

Proteins detected in plasma, urine, or buffy coat that correlate with metabolic changes. Further information on the column names is provided in the Patients and Methods and the legend for Table S13.

Year:

2025

Adverse events of bleeding reported in study subjects. In total, 17 events were reported in 16 patients, including three patients in Arm 1 who received BPM31510IV monotherapy (96-h infusion, n=1; 144-h infusion, n=2) and 13 in Arm 2 who received BPM31510IV in combination with chemotherapy (96-h infusion, n=7; 144-h infusion, n=6).

Year:

2025

. Proteomic analysis of plasma, urine, and buffy coat revealed a distinct association between BPM31510IV treatment and the regulation of complement and coagulation events. Total hits are the number of significant regression models for each protein (false-discovery rate

Year:

2025

Metabolites detected in plasma or urine that correlate with systemic protein changes. Further information on the column names is provided in the Patients and Methods and the legend for Table S13.

Year:

2025

Mean plasma concentrations of BPM31510IV at Cycle 1 Week 1. Graphs show mean BPM31510IV concentrations for patients receiving 96-h infusion in Arm 1 (A) and Arm 2 (B) and patients receiving 144-h infusion in Arm 1 (C) and Arm 2 (D).

Year:

2025

Results from exploratory studies. A, Representative 18 FDG PET/CT scans. A 53-year-old male with gastric adenocarcinoma with liver and lymph node metastases who received BPM31510IV monotherapy at 66 mg/kg. At the end of two cycles of BPM31510IV, there was a 40% decrease in SUV measures, complete resolution of activity in cervical and lymph node metastases, and decreased activity in the liver (yellow arrows). B, Waterfall plot showing best change in sum SUVmax for all patients with PET/CT results. For patients who crossed over from arm 1 to arm 2, PET/CT scan data after crossover were omitted from the analysis. C, Metabolomics analysis identifies metabolic activity involving fatty acylcarnitines associated with BPM31510IV treatment: enrichment for chemical subclasses among plasma metabolites shows a positive association with plasma CoQ 10 levels. Chemical subclasses ( y -axis) are shown in terms of their significance ( x -axis and dot color) and enrichment ratio relative to the reference metabolome (dot size).

Year:

2025

Purpose: BPM31510IV, a highly bioavailable intravenously administered coenzyme Q 10 (CoQ 10 ) formulation, was evaluated in a phase Ia/Ib study as monotherapy and in combination with chemotherapy in patients with advanced solid tumors. Patients and Methods: Using a 3 + 3 design, patients received twice-weekly intravenous infusions of BPM31510IV monotherapy (arm 1) or combined with gemcitabine, 5-fluorouracil/leucovorin, or docetaxel (arm 2); crossover between arms was permitted. Tumor response was assessed by RECIST1.1. Pharmacokinetic and multiomics pharmacodynamic (PD) analyses were performed on plasma and core biopsy samples. Results: A total of 97 patients were enrolled, 33 in arm 1 and 71 in arm 2 (seven patients crossed from arm 1 to arm 2). The MTD was 171 mg/kg for BPM31510IV monotherapy or with 5-fluorouracil/leucovorin and 110 mg/kg with gemcitabine or docetaxel. Four dose-limiting toxicities occurred (two in monotherapy; two in combination with chemotherapy). Most adverse events were coagulation-related, occurring in 96% of patients (grade ≥3 in 4%). Pharmacokinetics showed dose-proportional increases in CoQ 10 levels to supraphysiologic concentrations (>200×). In arm 1, there was one (3%) partial response (PR), with stable disease (SD) reported in eight (24%) patients. In arm 2, there was one (1%) PR, with SD reported in 25 (35%) patients. Fluorodeoxyglucose-PET imaging and PD data suggest a change in tumor metabolism from glycolysis to oxidative phosphorylation. Conclusions: BPM31510IV as monotherapy and in combination with chemotherapy was safe, with preliminary evidence of antitumor activity. High plasma CoQ 10 levels were achieved, inducing PD responses consistent with mitochondrial metabolic changes. These findings support continued clinical development of BPM31510IV. Significance: BPM31510IV is a lipid nanodispersion of oxidized CoQ 10 that alters the Warburg effect and displays anticancer activity. BPM31510IV seems to synergize with chemotherapy to induce cancer cell apoptosis, likely through mitochondrial priming. An initial phase I monotherapy study demonstrated that BPM31510IV is well tolerated in patients with advanced solid tumors. Based on these observations, the safety and preliminary antitumor activity of BPM31510IV were further explored in a phase Ia/Ib study in combination with chemotherapy. Results indicated that BPM31510IV monotherapy and BPM31510IV combined with chemotherapy are well tolerated, demonstrating preliminary evidence of antitumor activity and inducing physiologic and molecular changes consistent with altered mitochondrial metabolism. The most common adverse events were changes in coagulation parameters. Overall, this study provides valuable MTD and surrogate efficacy data that support the continued clinical development of BPM31510IV.

Year:

2025

Purpose: BPM31510IV, a highly bioavailable intravenously administered coenzyme Q10 (CoQ10) formulation, was evaluated in a phase Ia/Ib study as monotherapy and in combination with chemotherapy in patients with advanced solid tumors. Patients and Methods: Using a 3 + 3 design, patients received twice-weekly intravenous infusions of BPM31510IV monotherapy (arm 1) or combined with gemcitabine, 5-fluorouracil/leucovorin, or docetaxel (arm 2); crossover between arms was permitted. Tumor response was assessed by RECIST1.1. Pharmacokinetic and multiomics pharmacodynamic (PD) analyses were performed on plasma and core biopsy samples. Results: A total of 97 patients were enrolled, 33 in arm 1 and 71 in arm 2 (seven patients crossed from arm 1 to arm 2). The MTD was 171 mg/kg for BPM31510IV monotherapy or with 5-fluorouracil/leucovorin and 110 mg/kg with gemcitabine or docetaxel. Four dose-limiting toxicities occurred (two in monotherapy; two in combination with chemotherapy). Most adverse events were coagulation-related, occurring in 96% of patients (grade ≥3 in 4%). Pharmacokinetics showed dose-proportional increases in CoQ10 levels to supraphysiologic concentrations (>200×). In arm 1, there was one (3%) partial response (PR), with stable disease (SD) reported in eight (24%) patients. In arm 2, there was one (1%) PR, with SD reported in 25 (35%) patients. Fluorodeoxyglucose-PET imaging and PD data suggest a change in tumor metabolism from glycolysis to oxidative phosphorylation. Conclusions: BPM31510IV as monotherapy and in combination with chemotherapy was safe, with preliminary evidence of antitumor activity. High plasma CoQ10 levels were achieved, inducing PD responses consistent with mitochondrial metabolic changes. These findings support continued clinical development of BPM31510IV. Significance: BPM31510IV is a lipid nanodispersion of oxidized CoQ10 that alters the Warburg effect and displays anticancer activity. BPM31510IV seems to synergize with chemotherapy to induce cancer cell apoptosis, likely through mitochondrial priming. An initial phase I monotherapy study demonstrated that BPM31510IV is well tolerated in patients with advanced solid tumors. Based on these observations, the safety and preliminary antitumor activity of BPM31510IV were further explored in a phase Ia/Ib study in combination with chemotherapy. Results indicated that BPM31510IV monotherapy and BPM31510IV combined with chemotherapy are well tolerated, demonstrating preliminary evidence of antitumor activity and inducing physiologic and molecular changes consistent with altered mitochondrial metabolism. The most common adverse events were changes in coagulation parameters. Overall, this study provides valuable MTD and surrogate efficacy data that support the continued clinical development of BPM31510IV.

Year:

2025

Year:

2024

Year:

2024

Collaborators (16)

Shulin Zhang

Professor

University of Kentucky

UNITED STATES
View details

Scott Tagawa

Weill Cornell Medicine

UNITED STATES
View details

David Cognetti

department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho

UNITED STATES
View details

Ming-Yuan Chih

Associate Professor

University of Kentucky

UNITED STATES
View details

Manish A. Shah

Weill Cornell Medical College

UNITED STATES
View details

Vivek Subbiah

Professor of Medicine and of Pediatrics

Stanford University

UNITED STATES
View details

Qing Shao

Associate Professor

University of Kentucky

UNITED STATES
View details

Rangaprasad Sarangarajan

Associate Professor of Biomedical Sciences

Sam Houston State University

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Larry Harshyne

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Hunter Moseley

Professor

University of Kentucky

UNITED STATES
View details

Jennifer M. Johnson

Thomas Jefferson University

UNITED STATES
View details

Eliah S. Aronoff-Spencer

University of California

UNITED STATES
View details

Corey Baker

Assistant Professor

University of Southern California

UNITED STATES
View details

Rong Wang

Assistant Professor

Vanderbilt University

UNITED STATES
View details

Christine Brainson

University of Kentucky

UNITED STATES
View details